Speaker Profile
M.D., BA(Hons) FRACP, CEO, S2N.Bio
Biography
Dr. Brendon Boot is CEO and Managing Director of S2N.Bio. He trained as a neurologist in Sydney, Australia and Mayo Clinic. He spent 12 years on faculty at Harvard and Mass General Brigham. In industry, Brendon led the early development of numerous breakthrough programs in neurology, including the first ever disease-modifying therapies in Alzheimer (Aduhelm, Leqembi) and the first gene and pluripotent stem cell therapies developed for Parkinson’s Disease (VYAADC01, bemdaneprocel, ANPD001). He returned to Australia as an Entrepreneur In Residence at the IP Group before joining S2N in 2024.
Talk
Unique Cell Therapy Biotech with Profound Alzheimer PoC
Every day, stem cells in your brain’s memory center make 700 new neurons. In Alzheimer’s, you lose more cells than you make.
In a clinical trial of dogs with amyloid and tau, S2N's autologous cell therapy produced a 9 sd increase in synapses and significant memory improvements that lasted years.
Emerging Therapeutics Showcase:
S2N.Bio
S2N’s cell therapy tech is unique, our CMC closed and automated, and we're the only company that has reversed clinical decline in a large animal with Alzheimer pathology. If this effect is replicated in humans, patients in nursing home will return to independent living.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy
